title: Assessment of frequencies of lifestyle factors and polymorphisms of drug-metabolizing enzymes (NAT2, CYP2E1) in human hepatocellular carcinoma (HCC) patients in a department of surgical medicine--a pilot investigation.
abstract: The pathogenesis of human hepatocellular carcinoma (HCC) is a multistage process with the involvement of a multifactorial etiology. The role of drugs as risk factors has not been conclusively ascertained, but it appears that the use of oral contraceptives can be included. In the multifactorial etiology of human hepatocellular carcinoma (HCC), an association and interaction between genetic polymorphisms of xenobiotic metabolizing enzymes, lifestyle factors and cancer risk has been postulated. This pilot investigation examines the frequency of polymorphisms in selected genes (NAT2, CYP2E1) coding for xenobiotic metabolizing enzymes, and life-style habits (cigarette smoking, alcohol consumption) in 38 HCC patients. Genotyping of xenobiotic metabolizing enzymes was carried out using polymerase chain reaction--restriction fragment length polymorphism methods and DNA extracted from peripheral blood cells. In addition, HCC patients were interviewed with regard to their cigarette smoking habits and alcohol consumption using a standardized questionnaire. The results of this pilot investigation showed that the majority of the HCC patients smoke and consume alcohol. We found no predominance of slow acetylators (45%) or rapid acetylators (55%). 70.6% of slow acetylators were smokers. 86.5% of all patients with homozygote PstI/RsaI genotype also carried the homozygote DraI genotype, whereas 10.8% of all subjects with heterozygote PstI/RsaI genotype also carried the heterozygote DraI genotype. These genotype frequencies remain to be confirmed in a larger ethnic group. Whether polymorphisms of xenobiotic metabolizing enzymes is an important risk factor in (cigarette smoking-/alcohol consumption) HCC or not is currently being investigated in a case-control study in the same ethnic group.
authors.affiliation: Institute of Clinical Pharmacology, Friedrich Schiller University, Jena, Germany. katrin.farker@med.uni-jena.de
authors.forename: K
authors.initials: K
authors.lastname: Farker
authors.forename: U
authors.initials: U
authors.lastname: Schotte
authors.forename: J
authors.initials: J
authors.lastname: Scheele
authors.forename: A
authors.initials: A
authors.lastname: Hoffmann
mesh_terms: D000428:Alcohol Drinking / Q000009:adverse effects; D001191:Arylamine N-Acetyltransferase / Q000235:genetics*; D006528:Carcinoma, Hepatocellular / Q000201:enzymology* / Q000209:etiology; D019392:Cytochrome P-450 CYP2E1 / Q000235:genetics*; D005260:Female; D006801:Humans; D008019:Life Style; D008113:Liver Neoplasms / Q000201:enzymology* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011110:Polymorphism, Genetic; D012307:Risk Factors; D012907:Smoking / Q000009:adverse effects
chemical_list: D019392:Cytochrome P-450 CYP2E1; D001191:Arylamine N-Acetyltransferase; C478900:NAT2 protein, human